Results 51 to 60 of about 1,963 (217)

Распадаемость агломератов в процессе высвобождения из ингалятора [PDF]

, 2018
Представлены результаты экспериментальных исследований фракционного состава микронизированной активной фармацевтической субстанции Сальметерола ксинафоат при выходе из однодозового порошкового ингалятора.
Иванов, Н. А., Маркова, А. В., Сорокин, В. В.   +2 more
core   +2 more sources

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources

Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. [PDF]

, 2015
BACKGROUND: Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and medical visits.
Aalbers, Adams, Adams, Ahmad, Anderson, Barnes, Berger, Bijl-Hofland, Brown, Brozek, Bumbacea, Bush, Cates, Cates, Cates, Cowie, Crane, Dorinsky, Dorinsky, Ducharme, Ducharme, Ernst, FitzGerald, FitzGerald, Fowler, Godard, Godard, Harrison, Hernández, Ind, Johnston, Koenig, Koenig, Lemanske, Lipworth, Liu, McMahon, Nathan, Nathan, Nelson, Nelson, Ni Chroinin, Obase, Oppenheimer, Paggiaro, Paggiaro, Papi, Pruteanu, Reddel, Rumbak, Salpeter, Self, Shamsul, Slankard, Spycher, Tattersfield, Wilding, Zangrilli, Zhang, Zhang   +59 more
core   +1 more source

Does device matter for inhaled therapies in advanced chronic obstructive pulmonary disease (COPD)? A comparative trial of two devices

BMC Research Notes, 2019
Objective COPD patients have challenges for effective use of inhalers due to advanced age, fixed airflow obstruction and comorbid medical conditions. Published clinical trials investigate drug efficacy but rarely consider the inhaler device.
Haider Mannan, Soo Wei Foo, Belinda Cochrane   +2 more
doaj   +1 more source

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [PDF]

, 2010
Background An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in comparison with placebo in previous Cochrane reviews.
Aalbers, Aalbers, Altman, Barnes, Beach, Bleecker, Busse, Cates, Cates, Cates, Cates, Cates, Dahl, Ducharme, Ducharme, Ducharme, Giembycz, Higgins, Lasserson, Lipworth, Nelson, Ni Chroinin, Papi, Ringdal, Salpeter, Tamminen, Walters, Walters   +27 more
core   +2 more sources

Salmeterol Xinafoate

Drugs, 1991
Salmeterol xinafoate, like salbutamol (albuterol), is a saligenin derivative, and a selective beta 2-adrenoceptor agonist. It produces bronchodilation for at least 12 hours following inhalation of a single 50 micrograms dose. Salmeterol is intended for regular twice-daily treatment of reversible airways obstruction and not for immediate symptomatic ...
R N, Brogden, D, Faulds
openaire   +3 more sources

Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. [PDF]

, 2015
BACKGROUND: Poorly controlled asthma often leads to preventable exacerbations that require additional medications, as well as unscheduled hospital and clinic visits.Long-acting beta2-agonists (LABA) are commonly given to adults with asthma whose symptoms
Aalbers, Aaronson, Adams, Adams, Anderson, Barnes, Berger, Bijl-Hofland, Brown, Brozek, Bumbacea, Cates, Cates, Cowie, Crane, Dorinsky, Dorinsky, Ducharme, Ducharme, Ernst, FitzGerald, FitzGerland, Fowler, Godard, Harrison, Hoare, Ind, Johnston, Juniper, Koenig, Koenig, Lipworth, Liu, Nathan, Nathan, Nelson, Nelson, Obase, Paggiaro, Papi, Reddel, Salpeter, Self, Shamsul, Slankard, Tattersfield, Wilding, Zangrilli   +47 more
core   +1 more source

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: A Spanish National Healthcare System perspective [PDF]

, 2018
Background: A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in symptomatic ...
Alcázar-Navarrete, B., Asukai, Y., Driessen, M. T., García-Río, F., Miravitlles, Marc, Naya, I. P., Risebrough, N. A., Seewoodharry Buguth, B., Vallejo-Aparicio, L. A., Whalen, J.   +9 more
core   +4 more sources

Long-acting beta2-agonists for chronic obstructive pulmonary disease. [PDF]

, 2013
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up.
Aalbers, Allegra, Amgott, Anderson, Appleton, Arievich, Bateman, Bateman, Baumgartner, Beeh, Berger, Bleecker, Bleecker, Bogdan, Bogdan, Boyd, Boyd, Briggs, British Medical Association and the Royal Pharmaceutical Society of Great Britain, Brusasco, Brusasco, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Calverley, Campbell, Campbell, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Celli, Chapman, Chapman, Cheyne, Chong, Chong, Corhay, Dahl, Dahl, Dahl, Dahl, Dahl, Dahl, Dal Negro, Dal Negro, Doherty, Doherty, Doherty, Doherty, Donohue, Donohue, Donohue, Donohue, Effing, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Ferguson, Geake, Greefhorst, Greefhorst, Greefhorst, Gross, Hanania, Hanania, Hanrahan, Hanrahan, Hanrahan, Hanrahan, Hanrahan, Higgins, Hogan, Horstman, Hunjan, Hunjan, Hutchinson, Jenkins, Jenkins, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Jones, Karner, Karner, Karner, Karner, Karner, Keene, Kerwin, Kerwin, Khamis, Kliber, Kornmann, Kornmann, Kristufek, Kristufek, Kristufek, Lacasse, Laties, Littner, Lofdahl, Lofdahl, Lofdahl, Lofdahl, Mahler, Mahler, Mahler, Mahler, Matiz-Bueno, Matiz-Bueno, McDonough, McGarvey, Meer, Nannini, Nannini, Nannini, Nelson, Nelson, Nelson, Nelson, Nitschmann, Noord, Noord, Puhan, Qaseem, Rennard, Rennard, Rennard, Rennard, Rodrigo, Rossi, Rutten-van Molken, Rutten-van Mölken, Sacchetta, Sciurba, Song, Spencer, Spencer, Spencer, Spencer, Spencer, Spencer, Stahl, Steffensen, Steffensen, Stockley, Stockley, Szafranski, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Tashkin, Vestbo, Vestbo, Vestbo, Vestbo, Vogelmeier, Vogelmeier, Wadbo, Wang, Watkins, Welsh, Yang   +198 more
core   +1 more source

Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study [PDF]

, 2012
Introduction: The inhaled corticosteroid, fluticasone propionate (fluticasone), and the long-acting beta2-agonist, formoterol fumarate (formoterol), have been combined in a single aerosol inhaler (fluticasone/formoterol).
Aalbers, René, Bodzenta-Lukaszyk, Anna, Brusselle, Guy, Grothe, Birgit, McIver, Tammy   +4 more
core   +1 more source